Short Communication Open Access
Volume 2 | Issue 2 | DOI: https://doi.org/10.46439/allergy.2.020
The Pan Degenerate Amplification and Adaptation (PANDAA) assay: a solution for HIV-1 drug resistance testing in a resource limited setting?
Vinie Kouamou1,*, Alan M McGregor1
- 1Unit of Internal Medicine, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe
Corresponding Author
Vinie Kouamou, kvinie2005@yahoo.fr
Received Date: March 10, 2021
Accepted Date: May 24, 2021
Kouamou V, McGregor AM. The Pan Degenerate Amplification and Adaptation (PANDAA) assay: a solution for HIV-1 drug resistance testing in a resource limited setting?. J Allergy Infect Dis 2021; 2(2):33-35.
Copyright: © 2021 Kouamou V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies
Human immunodeficiency virus type 1 (HIV-1) continues to pose a significant global health challenge despite advances in combined antiretroviral therapy (cART), which has transformed HIV-1 infection from a fatal disease to a manageable chronic condition. However, cART is not curative, and its long-term use is associated with challenges such as pill burden, drug toxicities, and the emergence of drug-resistant viral strains.
Unique genotypic features of HIV-1 C gp41 membrane proximal external region variants during pregnancy relate to mother-to-child transmission via breastfeeding
Mother-to-child transmission (MTCT) through breastfeeding remains a major source of pediatric HIV-1 infection worldwide. To characterize plasma HIV-1 subtype C populations from infected mothers during pregnancy that related to subsequent breast milk transmission, an exploratory study was designed to apply next generation sequencing and a custom bioinformatics pipeline for HIV-1 gp41 extending from heptad repeat region 2 (HR2) through the membrane proximal external region (MPER) and the membrane spanning domain (MSD).
The Pan Degenerate Amplification and Adaptation (PANDAA) assay: a solution for HIV-1 drug resistance testing in a resource limited setting?
In resource limited settings (RLS), the resources and capacity to perform standard genotype resistance testing for the management of antiretroviral therapy (ART) drug resistance in People Living With HIV/AIDS (PLHIV) are limited. Therefore, in most instances, ART drug switches are based on unreliable clinical and laboratory data. Thus, such switching may occur unnecessarily or individuals may be switched to sub-optimal treatment, leading to the accumulation of drug resistance mutations (DRMs).
Stem cell–based strategies for HIV-1 remission: Emerging frontiers and translational challenges
Antiretroviral therapy (ART) has transformed HIV-1 from a fatal infection into a manageable chronic condition. Yet ART cannot eradicate latent viral reservoirs, necessitating lifelong adherence and leaving more than 38 million people worldwide without a definitive cure [1].